FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2073621732> ?p ?o ?g. }

• W2073621732 endingPage "A86" @default.
• W2073621732 startingPage "A85.3" @default.
• W2073621732 abstract "<h3>Background</h3> Apremilast (APR), an oral phosphodiesterase 4 inhibitor, works intracellularly to modulate inflammatory mediators. <h3>Objectives</h3> PALACE 3 compared APR vs placebo (PBO) in patients with active psoriatic arthritis (PsA) and at least 1 ≥2-cm psoriatic lesion at baseline (BL) despite prior DMARDs and/or biologics. <h3>Methods</h3> Patients were randomized 1:1:1 to PBO, APR 20 mg BID (APR20), or APR 30 mg BID (APR30) stratified by BL DMARD use. At wk 16, patients with <20% reduction in swollen and tender joint counts (SJC, TJC) were required to be re-randomized to APR20 or APR30 (early escape) if first randomized to PBO or remained on the initial APR dose. Patients continued treatment through wk 24. Stable concurrent DMARD therapy was allowed (MTX, sulfasalazine, leflunomide, or combination). Efficacy analyses were conducted using the per-protocol population (N=486). Missing data were handled using NRI for ACR response at wk 16 and LOCF for secondary endpoints. <h3>Results</h3> 505 patients were randomized and had comparable BL characteristics (mean TJC 20.0, SJC 11.4, HAQ-DI 1.157, DAS-28 4.57); 27.9% had prior biologic exposure and 8.7% were considered biologic failures. At BL, 60.6% were taking DMARDs, of which 85.6% were taking MTX (mean dose, 14.75 mg/wk). At wk 16, significantly more patients receiving APR20 (29.4%; <i>P</i>=.02) and APR30 (42.8%; <i>P</i><.0001) achieved the primary endpoint of ACR20 vs PBO (18.9%). Comparable results were seen with APR monotherapy or as combination therapy with DMARDs. At wk 24, significant improvements in secondary endpoints were seen with APR vs PBO (Table). APR was well tolerated. Adverse events (AEs) occurring in ≥5% of any group were diarrhea, nausea, headache, and URTI. Of APR-treated patients with AEs, the majority (>92%) AEs were mild or moderate. Discontinuations due to AEs were low across all treatment arms (6-8%). Serious AEs occurred in 9 (PBO), 3 (APR20), and 6 (APR30) patients. No systemic opportunistic infections (including reactivation or de novo TB) or lymphoma was observed. There was no greater risk of cardiovascular events. <h3>Conclusions</h3> APR significantly improved signs and symptoms of PsA and associated psoriasis and resulted in statistically and clinically meaningful improvements in physical function. APR was generally well tolerated with no new safety or laboratory signals detected. <h3>Disclosure of Interest</h3> C. Birbara Grant/research support from: Amgen, Lilly, Pfizer, Incyte, Merck, Bristol-Myers Squibb, F. Blanco Consultant for: Pfizer, Bioiberica, Gebro Farma, J. Crowley Grant/research support from: Abbvie, Amgen, Celgene, Janssen, Merck, Pfizer, Speakers bureau: Abbvie, C. Hu Employee of: Celgene Corporation, R. Stevens Employee of: Celgene Corporation, C. Edwards Grant/research support from: Pfizer, Consultant for: Samsung, Roche, Celgene, Speakers bureau: Roche, Pfizer, Abbott, GSK" @default.
• W2073621732 created "2016-06-24" @default.
• W2073621732 creator A5014411015 @default.
• W2073621732 creator A5019811024 @default.
• W2073621732 creator A5034131885 @default.
• W2073621732 creator A5047815768 @default.
• W2073621732 creator A5056014905 @default.
• W2073621732 creator A5080046861 @default.
• W2073621732 date "2013-06-01" @default.
• W2073621732 modified "2023-10-01" @default.
• W2073621732 title "OP0104 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis Including Current Skin Involvement: Results of a Phase 3, Randomized, Controlled Trial" @default.
• W2073621732 doi "https://doi.org/10.1136/annrheumdis-2013-eular.309" @default.
• W2073621732 hasPublicationYear "2013" @default.
• W2073621732 type Work @default.
• W2073621732 sameAs 2073621732 @default.
• W2073621732 citedByCount "5" @default.
• W2073621732 countsByYear W20736217322014 @default.
• W2073621732 countsByYear W20736217322015 @default.
• W2073621732 crossrefType "journal-article" @default.
• W2073621732 hasAuthorship W2073621732A5014411015 @default.
• W2073621732 hasAuthorship W2073621732A5019811024 @default.
• W2073621732 hasAuthorship W2073621732A5034131885 @default.
• W2073621732 hasAuthorship W2073621732A5047815768 @default.
• W2073621732 hasAuthorship W2073621732A5056014905 @default.
• W2073621732 hasAuthorship W2073621732A5080046861 @default.
• W2073621732 hasConcept C126322002 @default.
• W2073621732 hasConcept C142724271 @default.
• W2073621732 hasConcept C16005928 @default.
• W2073621732 hasConcept C168563851 @default.
• W2073621732 hasConcept C203092338 @default.
• W2073621732 hasConcept C204787440 @default.
• W2073621732 hasConcept C27081682 @default.
• W2073621732 hasConcept C2775905006 @default.
• W2073621732 hasConcept C2776260265 @default.
• W2073621732 hasConcept C2777575956 @default.
• W2073621732 hasConcept C2780564577 @default.
• W2073621732 hasConcept C2781427535 @default.
• W2073621732 hasConcept C2908647359 @default.
• W2073621732 hasConcept C71924100 @default.
• W2073621732 hasConcept C90924648 @default.
• W2073621732 hasConcept C99454951 @default.
• W2073621732 hasConceptScore W2073621732C126322002 @default.
• W2073621732 hasConceptScore W2073621732C142724271 @default.
• W2073621732 hasConceptScore W2073621732C16005928 @default.
• W2073621732 hasConceptScore W2073621732C168563851 @default.
• W2073621732 hasConceptScore W2073621732C203092338 @default.
• W2073621732 hasConceptScore W2073621732C204787440 @default.
• W2073621732 hasConceptScore W2073621732C27081682 @default.
• W2073621732 hasConceptScore W2073621732C2775905006 @default.
• W2073621732 hasConceptScore W2073621732C2776260265 @default.
• W2073621732 hasConceptScore W2073621732C2777575956 @default.
• W2073621732 hasConceptScore W2073621732C2780564577 @default.
• W2073621732 hasConceptScore W2073621732C2781427535 @default.
• W2073621732 hasConceptScore W2073621732C2908647359 @default.
• W2073621732 hasConceptScore W2073621732C71924100 @default.
• W2073621732 hasConceptScore W2073621732C90924648 @default.
• W2073621732 hasConceptScore W2073621732C99454951 @default.
• W2073621732 hasIssue "Suppl 3" @default.
• W2073621732 hasLocation W20736217321 @default.
• W2073621732 hasOpenAccess W2073621732 @default.
• W2073621732 hasPrimaryLocation W20736217321 @default.
• W2073621732 hasRelatedWork W1998954793 @default.
• W2073621732 hasRelatedWork W2034115370 @default.
• W2073621732 hasRelatedWork W2121588356 @default.
• W2073621732 hasRelatedWork W2155073280 @default.
• W2073621732 hasRelatedWork W2185164199 @default.
• W2073621732 hasRelatedWork W2766291043 @default.
• W2073621732 hasRelatedWork W3119463521 @default.
• W2073621732 hasRelatedWork W3139921020 @default.
• W2073621732 hasRelatedWork W4295807681 @default.
• W2073621732 hasRelatedWork W4306156432 @default.
• W2073621732 hasVolume "72" @default.
• W2073621732 isParatext "false" @default.
• W2073621732 isRetracted "false" @default.
• W2073621732 magId "2073621732" @default.
• W2073621732 workType "article" @default.